The	The	DT	0
problem	problem	NN	0
Three	Three	CD	0
published	published	NNS	0
[	[	-LRB-	0
1	1	CD	0
2	2	CD	0
3	3	CD	0
]	]	-RRB-	0
and	and	CC	0
one	one	CD	0
recently	recently	RB	0
presented	presented	VBN	0
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
randomized	randomized	JJ	B-NP
placebo-controlled	placebo-controlled	JJ	I-NP
clinical	clinical	JJ	I-NP
trial	trial	NN	I-NP
have	have	VBP	0
unequivocally	unequivocally	RB	0
demonstrated	demonstrated	VBN	0
that	that	IN	0
3-Hydroxy-3-methylgluatryl	3-Hydroxy-3-methylgluatryl	NNP	0
coenzyme	coenzyme	VBD	0
A	A	DT	0
(	(	-LRB-	0
HMG	HMG	NNP	0
CoA	CoA	NNP	0
)	)	-RRB-	0
reductase	reductase	NN	B-NP
inhibitor	inhibitor	NN	I-NP
(	(	-LRB-	0
statin	statin	NN	B-NP
)	)	-RRB-	0
reduce	reduce	VB	0
the	the	DT	0
morbidity	morbidity	NN	0
and	and	CC	0
mortality	mortality	NN	0
associated	associated	VBN	0
with	with	IN	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
.	.	.	0
These	These	DT	0
trials	trials	NNS	0
found	found	VBD	0
that	that	IN	0
when	when	WRB	0
compared	compared	VBN	0
with	with	IN	0
placebo	placebo	NN	0
,	,	,	0
statins	statins	VBD	0
significantly	significantly	RB	0
reduced	reduced	VBN	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
death	death	NN	0
,	,	,	0
myocardial	myocardial	JJ	B-NP
infarction	infarction	NN	I-NP
,	,	,	0
unstable	unstable	JJ	0
angina	angina	NN	0
,	,	,	0
percutaneous	percutaneous	NN	B-NP
and	and	CC	0
surgical	surgical	JJ	B-NP
coronary	coronary	JJ	I-NP
revascularization	revascularization	NN	I-NP
,	,	,	0
and	and	CC	0
stroke	stroke	NN	0
in	in	IN	0
persons	persons	NNS	0
with	with	IN	0
stable	stable	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
.	.	.	0
Because	Because	IN	0
patients	patients	NNS	0
who	who	WP	0
had	had	VBD	0
experienced	experienced	VBN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
within	within	IN	0
three	three	CD	0
to	to	TO	0
six	six	CD	0
months	months	NNS	0
of	of	IN	0
enrollment	enrollment	NN	0
were	were	VBD	0
excluded	excluded	VBN	0
,	,	,	0
these	these	DT	0
trials	trials	NNS	0
did	did	VBD	0
not	not	RB	0
assess	assess	VB	0
the	the	DT	0
effect	effect	NN	0
of	of	IN	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
on	on	IN	0
adverse	adverse	JJ	0
cardiovascular	cardiovascular	JJ	B-NP
event	event	NN	I-NP
in	in	IN	0
those	those	DT	0
with	with	IN	0
recently	recently	RB	0
unstable	unstable	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
.	.	.	0
Whether	Whether	IN	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
would	would	MD	0
provide	provide	VB	0
incremental	incremental	JJ	B-NP
benefit	benefit	NN	I-NP
if	if	IN	0
initiated	initiated	VBN	0
immediately	immediately	RB	0
following	following	VBG	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
is	is	VBZ	0
an	an	DT	0
important	important	JJ	0
issue	issue	NN	0
as	as	IN	0
the	the	DT	0
risk	risk	NN	0
of	of	IN	0
a	a	DT	0
recurrent	recurrent	JJ	0
adverse	adverse	JJ	0
cardiac	cardiac	JJ	B-NP
event	event	NN	I-NP
is	is	VBZ	0
much	much	RB	0
greater	greater	JJR	0
in	in	IN	0
patients	patients	NNS	0
with	with	IN	0
unstable	unstable	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
than	than	IN	0
in	in	IN	0
the	the	DT	0
stable	stable	JJ	0
setting	setting	NN	0
.	.	.	0
The	The	DT	0
Myocardial	Myocardial	NNP	B-NP
Ischemia	Ischemia	NNP	I-NP
Reduction	Reduction	NNP	I-NP
with	with	IN	0
Aggressive	Aggressive	NNP	B-NP
Cholesterol	Cholesterol	NNP	I-NP
Lowering	Lowering	NNP	0
(	(	-LRB-	0
MIRACL	MIRACL	NNP	0
)	)	-RRB-	0
trial	trial	NN	0
set	set	VBN	0
out	out	RP	0
to	to	TO	0
answer	answer	VB	0
this	this	DT	0
question	question	NN	0
.	.	.	0
The	The	DT	0
answer	answer	NN	0
?	?	.	0
MIRACL	MIRACL	NNP	B-NP
enrolled	enrolled	VBD	0
3,086	3,086	CD	0
patients	patients	NNS	0
within	within	IN	0
24-96	24-96	CD	0
hours	hours	NNS	0
(	(	-LRB-	0
mean	mean	VB	0
63	63	CD	0
hours	hours	NNS	0
)	)	-RRB-	0
of	of	IN	0
admission	admission	NN	B-NP
for	for	IN	0
unstable	unstable	JJ	0
angina	angina	NN	0
or	or	CC	0
a	a	DT	0
non-Q-wave	non-Q-wave	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
and	and	CC	0
randomized	randomized	VBD	0
them	them	PRP	0
to	to	TO	0
16	16	CD	0
weeks	weeks	NNS	0
of	of	IN	0
atorvastatin	atorvastatin	CD	B-NP
80	80	CD	0
mg	mg	NN	B-NP
or	or	CC	0
placebo	placebo	VBP	0
once	once	RB	0
daily	daily	JJ	0
[	[	-LRB-	0
5	5	LS	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
major	major	JJ	0
exclusion	exclusion	NN	B-NP
criterion	criterion	NN	I-NP
were	were	VBD	0
:	:	:	0
total	total	JJ	B-NP
cholesterol	cholesterol	NN	I-NP
level	level	NN	I-NP
greater	greater	JJR	0
than	than	IN	0
270	270	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
dL	dL	NN	I-NP
;	;	:	0
Q-wave	Q-wave	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
on	on	IN	0
admission	admission	NN	B-NP
or	or	CC	0
during	during	IN	0
the	the	DT	0
previous	previous	JJ	0
month	month	NN	0
;	;	:	0
and	and	CC	0
,	,	,	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
in	in	IN	0
the	the	DT	0
months	months	NNS	0
before	before	IN	0
admission	admission	NN	B-NP
,	,	,	0
during	during	IN	0
the	the	DT	0
index	index	NN	B-NP
hospitalization	hospitalization	NN	I-NP
or	or	CC	0
anticipated	anticipated	VBN	0
following	following	VBG	0
hospital	hospital	NN	B-NP
discharge	discharge	NN	I-NP
.	.	.	0
The	The	DT	0
primary	primary	JJ	B-NP
efficacy	efficacy	JJ	I-NP
endpoint	endpoint	NN	I-NP
was	was	VBD	0
a	a	DT	0
composite	composite	JJ	0
of	of	IN	0
death	death	NN	0
,	,	,	0
non-fatal	non-fatal	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
,	,	,	0
resuscitated	resuscitated	JJ	0
sudden	sudden	JJ	0
cardiac	cardiac	JJ	B-NP
death	death	NN	I-NP
or	or	CC	0
emergent	emergent	JJ	0
rehospitalization	rehospitalization	NN	B-NP
for	for	IN	0
worsening	worsening	VBG	0
symptomatic	symptomatic	JJ	B-NP
myocardial	myocardial	JJ	I-NP
ischemia	ischemia	NN	I-NP
.	.	.	0
included	included	VBD	B-NP
stroke	stroke	NN	I-NP
secondary	secondary	JJ	I-NP
endpoint	endpoint	NN	I-NP
,	,	,	0
worsening	worsening	VBG	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
,	,	,	0
need	need	VBP	0
for	for	IN	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
and	and	CC	0
change	change	NN	0
in	in	IN	0
lipid	lipid	JJ	B-NP
level	level	JJ	I-NP
throughout	throughout	IN	0
the	the	DT	0
study	study	NN	0
.	.	.	0
On	On	IN	0
average	average	NN	0
,	,	,	0
patients	patients	NNS	0
were	were	VBD	0
65	65	CD	0
years	years	NNS	0
of	of	IN	0
age	age	NN	0
,	,	,	0
approximately	approximately	RB	0
65	65	CD	0
%	%	NN	0
were	were	VBD	0
men	men	NNS	0
,	,	,	0
86	86	CD	0
%	%	NN	0
Caucasian	Caucasian	NNP	B-NP
and	and	CC	0
the	the	DT	0
mean	mean	JJ	0
baseline	baseline	NN	B-NP
low	low	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
(	(	-LRB-	0
low	low	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
)	)	-RRB-	0
cholesterol	cholesterol	NN	B-NP
level	level	NN	I-NP
was	was	VBD	0
124	124	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
dL	dL	NN	I-NP
.	.	.	0
Atorvastatin	Atorvastatin	JJ	B-NP
treatment	treatment	NN	I-NP
was	was	VBD	0
associated	associated	VBN	0
with	with	IN	0
a	a	DT	0
2.6	2.6	CD	0
%	%	NN	0
absolute	absolute	JJ	0
reduction	reduction	NN	0
in	in	IN	0
the	the	DT	0
risk	risk	NN	0
of	of	IN	0
the	the	DT	0
primary	primary	JJ	B-NP
endpoint	endpoint	NN	I-NP
(	(	-LRB-	0
14.8	14.8	CD	0
%	%	NN	0
vs.	vs.	IN	0
17.4	17.4	CD	0
%	%	NN	0
;	;	:	0
RR	RR	NNP	B-NP
relative	relative	JJ	I-NP
risk	risk	NN	I-NP
[	[	-LRB-	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
]	]	-RRB-	0
0.84	0.84	CD	0
,	,	,	0
95	95	CD	0
%	%	NN	0
confidence	confidence	NN	B-NP
interval	interval	NN	I-NP
[	[	-LRB-	0
CI	CI	NNP	0
]	]	-RRB-	0
0.70-1.00	0.70-1.00	NNP	0
,	,	,	0
p	p	VBG	0
=	=	SYM	0
0.048	0.048	CD	0
)	)	-RRB-	0
.	.	.	0
This	This	DT	0
reduction	reduction	NN	0
was	was	VBD	0
primarily	primarily	RB	0
driven	driven	VBN	0
by	by	IN	0
the	the	DT	0
2.2	2.2	CD	0
%	%	NN	0
absolute	absolute	JJ	0
reduction	reduction	NN	0
in	in	IN	0
incidence	incidence	NN	0
of	of	IN	0
emergent	emergent	JJ	0
symptomatic	symptomatic	JJ	B-NP
myocardial	myocardial	NN	I-NP
ischemia	ischemia	NN	I-NP
rehospitalization	rehospitalization	NN	I-NP
(	(	-LRB-	0
6.2	6.2	CD	0
%	%	NN	0
vs.	vs.	IN	0
8.4	8.4	CD	0
%	%	NN	0
;	;	:	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
0.74	0.74	NNP	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
0.57-0.95	0.57-0.95	NNP	0
,	,	,	0
p	p	VBG	0
=	=	SYM	0
0.02	0.02	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
risk	risk	NN	0
of	of	IN	0
death	death	NN	0
,	,	,	0
nonfatal	nonfatal	NN	B-NP
myocardial	myocardial	NN	I-NP
infarction	infarction	NN	I-NP
and	and	CC	0
resuscitated	resuscitated	JJ	0
sudden	sudden	JJ	0
cardiac	cardiac	JJ	B-NP
death	death	NN	I-NP
were	were	VBD	0
each	each	DT	0
no	no	DT	0
different	different	JJ	0
between	between	IN	0
the	the	DT	0
two	two	CD	0
groups	groups	NNS	0
.	.	.	0
While	While	IN	0
there	there	EX	0
were	were	VBD	0
no	no	DT	0
significant	significant	JJ	0
differences	differences	NNS	0
in	in	IN	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
worsening	worsening	VBG	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
or	or	CC	0
need	need	NN	0
for	for	IN	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
,	,	,	0
atorvastatin	atorvastatin	NN	B-NP
did	did	VBD	0
reduce	reduce	VB	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
fatal	fatal	JJ	0
or	or	CC	0
non-fatal	non-fatal	JJ	B-NP
stroke	stroke	NN	I-NP
by	by	IN	0
0.8	0.8	CD	0
%	%	NN	0
(	(	-LRB-	0
0.8	0.8	CD	0
%	%	NN	0
vs.	vs.	IN	0
1.6	1.6	CD	0
%	%	NN	0
;	;	:	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
0.50	0.50	NNP	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
0.26-0.99	0.26-0.99	NNP	0
,	,	,	0
p	p	VBG	0
=	=	SYM	0
0.045	0.045	CD	0
)	)	-RRB-	0
.	.	.	0
Atorvastatin	Atorvastatin	NNP	B-NP
also	also	RB	0
significantly	significantly	RB	0
reduced	reduced	VBN	0
total	total	JJ	0
and	and	CC	0
LDL	LDL	NNP	B-NP
cholesterol	cholesterol	NN	I-NP
and	and	CC	0
triglyceride	triglyceride	JJ	B-NP
level	level	JJ	I-NP
but	but	CC	0
did	did	VBD	0
not	not	RB	0
significantly	significantly	RB	0
change	change	VB	0
high	high	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
(	(	-LRB-	0
high	high	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
)	)	-RRB-	0
cholesterol	cholesterol	NN	B-NP
by	by	IN	0
16	16	CD	0
weeks	weeks	NNS	0
.	.	.	0
By	By	IN	0
16	16	CD	0
weeks	weeks	NNS	0
,	,	,	0
the	the	DT	0
adjusted	adjusted	JJ	0
mean	mean	JJ	0
LDL	LDL	NNP	B-NP
cholesterol	cholesterol	NN	I-NP
decreased	decreased	VBD	0
to	to	TO	0
72	72	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
dL	dL	NN	I-NP
in	in	IN	0
atorvastatin-treated	atorvastatin-treated	JJ	B-NP
patient	patient	JJ	I-NP
but	but	CC	0
increased	increased	VBN	0
to	to	TO	0
135	135	CD	0
mg	mg	CD	B-NP
/	/	CD	I-NP
dL	dL	NN	I-NP
among	among	IN	0
placebo-treated	placebo-treated	JJ	0
patients	patients	NNS	0
.	.	.	0
No	No	DT	0
serious	serious	JJ	0
adverse	adverse	JJ	0
events	events	NNS	0
occurred	occurred	VBD	0
as	as	IN	0
the	the	DT	0
result	result	NN	0
of	of	IN	0
treatment	treatment	NN	0
with	with	IN	0
atorvastatin	atorvastatin	NN	B-NP
,	,	,	0
although	although	IN	0
reversible	reversible	JJ	0
liver	liver	NN	B-NP
transaminasa	transaminasa	NN	I-NP
elevation	elevation	VBP	I-NP
more	more	JJR	0
than	than	IN	0
three	three	CD	0
times	times	NNS	0
the	the	DT	0
upper	upper	JJ	0
limit	limit	NN	0
of	of	IN	0
normal	normal	JJ	B-NP
occurred	occurred	NN	I-NP
in	in	IN	0
2.5	2.5	CD	0
%	%	NN	0
of	of	IN	0
atorvastatin-treated	atorvastatin-treated	JJ	B-NP
versus	versus	IN	0
0.6	0.6	CD	0
%	%	NN	0
of	of	IN	0
placebo-treated	placebo-treated	JJ	0
patients	patients	NNS	0
(	(	-LRB-	0
p	p	FW	0
<	<	SYM	0
0.001	0.001	FW	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
MIRACuLous	MIRACuLous	JJ	0
The	The	DT	0
efficacy	efficacy	NN	0
and	and	CC	0
safety	safety	NN	0
findings	findings	NNS	0
from	from	IN	0
MIRACL	MIRACL	NNP	B-NP
were	were	VBD	0
unique	unique	JJ	0
for	for	IN	0
a	a	DT	0
number	number	NN	0
of	of	IN	0
reasons	reasons	NNS	0
.	.	.	0
Although	Although	IN	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
was	was	VBD	0
associated	associated	VBN	0
with	with	IN	0
a	a	DT	0
significantly	significantly	RB	0
lower	lower	JJR	0
mortality	mortality	NN	0
when	when	WRB	0
initiated	initiated	VBN	0
early	early	RB	0
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
in	in	IN	0
two	two	CD	0
large	large	JJ	0
observational	observational	JJ	B-NP
study	study	NN	I-NP
[	[	-LRB-	0
6	6	CD	0
7	7	CD	0
]	]	-RRB-	0
,	,	,	0
MIRACL	MIRACL	NNP	B-NP
was	was	VBD	0
the	the	DT	0
first	first	JJ	0
randomized	randomized	JJ	B-NP
trial	trial	NN	I-NP
to	to	TO	0
suggest	suggest	VB	0
that	that	IN	0
statin	statin	NN	B-NP
confer	confer	VBP	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
in	in	IN	0
this	this	DT	0
setting	setting	NN	0
.	.	.	0
It	It	PRP	0
was	was	VBD	0
also	also	RB	0
the	the	DT	0
first	first	JJ	0
trial	trial	NN	0
to	to	TO	0
identify	identify	VB	0
a	a	DT	0
short-term	short-term	JJ	0
(	(	-LRB-	0
ie	ie	UH	B-NP
,	,	,	0
within	within	IN	0
16	16	CD	0
weeks	weeks	NNS	0
)	)	-RRB-	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
from	from	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
;	;	:	0
in	in	IN	0
previous	previous	JJ	0
secondary	secondary	JJ	B-NP
prevention	prevention	NN	I-NP
trial	trial	NN	I-NP
,	,	,	0
the	the	DT	0
benefit	benefit	NN	0
of	of	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
was	was	VBD	0
not	not	RB	0
evident	evident	JJ	0
for	for	IN	0
one	one	CD	0
to	to	TO	0
two	two	CD	0
years	years	NNS	0
.	.	.	0
And	And	CC	0
,	,	,	0
while	while	IN	0
clinical	clinical	JJ	B-NP
trial	trial	NN	I-NP
safety	safety	NN	I-NP
endpoint	endpoint	NN	I-NP
may	may	MD	0
be	be	VB	0
considered	considered	VBN	0
less	less	RBR	0
glamorous	glamorous	JJ	0
,	,	,	0
MIRACL	MIRACL	NNP	0
's	's	POS	0
most	most	RBS	0
important	important	JJ	0
contribution	contribution	NN	B-NP
may	may	MD	0
have	have	VB	0
been	been	VBN	0
that	that	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
high-dose	high-dose	JJ	I-NP
was	was	VBD	0
not	not	RB	0
associated	associated	VBN	0
with	with	IN	0
serious	serious	JJ	B-NP
harm	harm	NN	I-NP
,	,	,	0
despite	despite	IN	0
its	its	PRP$	0
use	use	NN	0
in	in	IN	0
the	the	DT	0
unstable	unstable	JJ	0
setting	setting	NN	0
.	.	.	0
Earlier	Earlier	RBR	0
secondary	secondary	JJ	B-NP
prevention	prevention	NN	I-NP
statin	statin	NN	I-NP
trial	trial	NN	I-NP
had	had	VBD	0
excluded	excluded	VBN	0
patients	patients	NNS	0
with	with	IN	0
unstable	unstable	JJ	0
coronary	coronary	NNS	B-NP
syndrome	syndrome	NN	I-NP
largely	largely	RB	0
out	out	RB	0
of	of	IN	0
theoretical	theoretical	JJ	B-NP
concern	concern	NN	I-NP
that	that	IN	0
statin-mediated	statin-mediated	JJ	B-NP
reduction	reduction	NN	I-NP
in	in	IN	0
vascular	vascular	JJ	B-NP
smooth	smooth	JJ	I-NP
muscle	muscle	NN	I-NP
cell	cell	NN	I-NP
proliferation	proliferation	NN	I-NP
might	might	MD	0
destabilize	destabilize	VB	0
healing	healing	JJ	0
plaque	plaque	NN	0
.	.	.	0
That	That	IN	0
no	no	DT	0
harm	harm	NN	0
resulted	resulted	VBD	0
from	from	IN	0
this	this	DT	0
aggressive	aggressive	JJ	B-NP
treatment	treatment	NN	I-NP
strategy	strategy	NN	I-NP
should	should	MD	0
allay	allay	VB	0
theoretical	theoretical	JJ	B-NP
fear	fear	NN	I-NP
and	and	CC	0
by	by	IN	0
doing	doing	VBG	0
so	so	RB	0
remove	remove	VB	0
a	a	DT	0
major	major	JJ	0
obstacle	obstacle	NN	0
to	to	TO	0
the	the	DT	0
lipid-lowing	lipid-lowing	JJ	B-NP
therapy	therapy	NN	I-NP
inpatient	inpatient	JJ	I-NP
initiation	initiation	NN	I-NP
after	after	IN	0
coronary	coronary	JJ	B-NP
event	event	NN	I-NP
.	.	.	0
The	The	DT	0
not	not	RB	0
so	so	RB	0
MIRACuLous	MIRACuLous	JJ	0
Despite	Despite	IN	0
these	these	DT	0
unique	unique	JJ	0
and	and	CC	0
important	important	JJ	0
findings	findings	NNS	0
,	,	,	0
there	there	EX	0
were	were	VBD	0
a	a	DT	0
number	number	NN	0
of	of	IN	0
inherent	inherent	JJ	0
study	study	NN	B-NP
limitation	limitation	NN	I-NP
worth	worth	IN	0
noting	noting	VBG	0
.	.	.	0
First	First	NNP	0
and	and	CC	0
foremost	foremost	RB	0
,	,	,	0
the	the	DT	0
possibility	possibility	NN	0
of	of	IN	0
a	a	DT	0
null	null	JJ	0
treatment	treatment	NN	B-NP
effect	effect	NN	I-NP
cannot	cannot	RB	0
be	be	VB	0
ignored	ignored	VBN	0
given	given	VBN	0
the	the	DT	0
wide	wide	JJ	0
confidence	confidence	NN	B-NP
interval	interval	NN	I-NP
(	(	-LRB-	0
and	and	CC	0
hence	hence	RB	0
marginally	marginally	RB	0
significant	significant	JJ	0
p	p	JJ	B-NP
value	value	NN	I-NP
of	of	IN	0
0.048	0.048	CD	0
)	)	-RRB-	0
for	for	IN	0
the	the	DT	0
effect	effect	NN	0
of	of	IN	0
atorvastatin	atorvastatin	NN	B-NP
on	on	IN	0
the	the	DT	0
primary	primary	JJ	B-NP
efficacy	efficacy	JJ	I-NP
endpoint	endpoint	NN	I-NP
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
while	while	IN	0
the	the	DT	0
number	number	NN	0
of	of	IN	0
patients	patients	NNS	0
lost	lost	VBD	0
to	to	TO	0
follow	follow	VB	0
up	up	RB	0
was	was	VBD	0
small	small	JJ	0
,	,	,	0
if	if	IN	0
adverse	adverse	JJ	0
events	events	NNS	0
had	had	VBD	0
occurred	occurred	VBN	0
in	in	IN	0
those	those	DT	0
treated	treated	VBN	0
with	with	IN	0
atorvastatin	atorvastatin	NN	B-NP
(	(	-LRB-	0
n	n	CD	0
=	=	SYM	0
3	3	LS	0
)	)	-RRB-	0
but	but	CC	0
not	not	RB	0
placebo	placebo	JJ	0
(	(	-LRB-	0
n	n	CD	0
=	=	SYM	0
8	8	CD	0
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
overall	overall	JJ	0
trial	trial	NN	B-NP
result	result	NN	I-NP
may	may	MD	0
have	have	VB	0
been	been	VBN	0
neutral	neutral	JJ	0
rather	rather	RB	0
than	than	IN	0
positive	positive	JJ	0
.	.	.	0
The	The	DT	0
types	types	NNS	0
of	of	IN	0
events	events	NNS	0
prevented	prevented	VBN	0
in	in	IN	0
MIRACL	MIRACL	NNP	B-NP
are	are	VBP	0
also	also	RB	0
worth	worth	JJ	0
noting	noting	NN	0
.	.	.	0
While	While	IN	0
rehospitalization	rehospitalization	NN	B-NP
for	for	IN	0
recurrent	recurrent	JJ	0
myocardial	myocardial	JJ	B-NP
ischemia	ischemia	NN	I-NP
is	is	VBZ	0
an	an	DT	0
important	important	JJ	0
determinant	determinant	NN	B-NP
of	of	IN	0
quality	quality	NN	0
of	of	IN	0
life	life	NN	0
and	and	CC	0
health	health	NN	B-NP
care	care	NN	I-NP
cost	cost	NN	I-NP
,	,	,	0
other	other	JJ	0
important	important	JJ	0
endpoint	endpoint	NN	B-NP
were	were	VBD	0
not	not	RB	0
significantly	significantly	RB	0
affected	affected	VBN	0
(	(	-LRB-	0
eg	eg	UH	B-NP
,	,	,	0
death	death	NN	0
,	,	,	0
myocardial	myocardial	JJ	B-NP
infarction	infarction	NN	I-NP
,	,	,	0
resuscitated	resuscitated	JJ	0
sudden	sudden	JJ	0
cardiac	cardiac	JJ	B-NP
death	death	NN	I-NP
,	,	,	0
worsening	worsening	VBG	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
,	,	,	0
need	need	VBP	0
for	for	IN	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
,	,	,	0
etc	etc	FW	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
question	question	NN	0
of	of	IN	0
whether	whether	IN	0
statin	statin	NN	B-NP
can	can	MD	0
prevent	prevent	VB	0
these	these	DT	0
and	and	CC	0
other	other	JJ	0
adverse	adverse	JJ	0
events	events	NNS	0
when	when	WRB	0
initiated	initiated	VBN	0
soon	soon	RB	0
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
will	will	MD	0
require	require	VB	0
further	further	JJ	0
study	study	NN	0
.	.	.	0
The	The	DT	0
short	short	JJ	0
duration	duration	NN	0
of	of	IN	0
follow-up	follow-up	NNP	0
is	is	VBZ	0
also	also	RB	0
particularly	particularly	RB	0
troubling	troubling	JJ	0
.	.	.	0
While	While	IN	0
it	it	PRP	0
is	is	VBZ	0
impressive	impressive	JJ	0
that	that	IN	0
a	a	DT	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
was	was	VBD	0
realized	realized	VBN	0
after	after	IN	0
only	only	RB	0
16	16	CD	0
weeks	weeks	NNS	0
of	of	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
,	,	,	0
the	the	DT	0
increased	increased	JJ	0
risk	risk	NN	0
of	of	IN	0
adverse	adverse	JJ	0
clinical	clinical	JJ	B-NP
event	event	NN	I-NP
persists	persists	VBZ	0
throughout	throughout	IN	0
the	the	DT	0
year	year	NN	0
following	following	VBG	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
.	.	.	0
Without	Without	IN	0
longer	longer	JJR	0
clinical	clinical	NNS	0
follow	follow	VBP	0
up	up	RB	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
not	not	RB	0
possible	possible	JJ	0
to	to	TO	0
assess	assess	VB	0
the	the	DT	0
intermediate-term	intermediate-term	JJ	B-NP
effect	effect	NN	I-NP
(	(	-LRB-	0
if	if	IN	0
any	any	DT	0
)	)	-RRB-	0
of	of	IN	0
atorvastatin	atorvastatin	NN	B-NP
on	on	IN	0
hard	hard	JJ	0
endpoints	endpoints	JJ	0
such	such	JJ	0
as	as	IN	0
death	death	NN	0
or	or	CC	0
myocardial	myocardial	JJ	B-NP
infarction	infarction	NN	I-NP
.	.	.	0
To	To	TO	0
do	do	VB	0
so	so	RB	0
would	would	MD	0
be	be	VB	0
critical	critical	JJ	0
in	in	IN	0
light	light	NN	0
of	of	IN	0
the	the	DT	0
lack	lack	NN	0
of	of	IN	0
effect	effect	NN	0
on	on	IN	0
these	these	DT	0
important	important	JJ	0
endpoint	endpoint	NN	B-NP
at	at	IN	0
16	16	CD	0
weeks	weeks	NNS	0
.	.	.	0
Unfortunately	Unfortunately	RB	0
,	,	,	0
no	no	DT	0
late	late	JJ	0
clinical	clinical	NNS	0
follow	follow	VBP	0
up	up	RB	0
is	is	VBZ	0
planned	planned	VBN	0
.	.	.	0
There	There	EX	0
were	were	VBD	0
also	also	RB	0
a	a	DT	0
number	number	NN	0
of	of	IN	0
limitations	limitations	NNS	0
that	that	WDT	0
may	may	MD	0
have	have	VB	0
hampered	hampered	VBN	0
the	the	DT	0
study	study	NN	0
's	's	POS	0
generalizability	generalizability	NN	B-NP
.	.	.	0
First	First	NNP	0
,	,	,	0
patients	patients	NNS	0
who	who	WP	0
underwent	underwent	VBD	0
recent	recent	JJ	0
revascularization	revascularization	NN	B-NP
or	or	CC	0
in	in	IN	0
whom	whom	WP	0
it	it	PRP	0
was	was	VBD	0
planned	planned	VBN	0
were	were	VBD	0
excluded	excluded	VBN	0
.	.	.	0
Specifically	Specifically	RB	0
,	,	,	0
patients	patients	NNS	0
who	who	WP	0
underwent	underwent	VBD	0
percutaneou	percutaneou	NN	B-NP
transluminal	transluminal	NN	I-NP
coronary	coronary	JJ	I-NP
angioplasty	angioplasty	NN	I-NP
(	(	-LRB-	0
percutaneou	percutaneou	NN	B-NP
transluminal	transluminal	NN	I-NP
coronary	coronary	JJ	I-NP
angioplasty	angioplasty	NN	I-NP
)	)	-RRB-	0
or	or	CC	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
bypass	bypass	NN	I-NP
graft	graft	NN	I-NP
(	(	-LRB-	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
bypass	bypass	NN	I-NP
graft	graft	NN	I-NP
)	)	-RRB-	0
surgery	surgery	NN	0
within	within	IN	0
the	the	DT	0
previous	previous	JJ	0
three	three	CD	0
or	or	CC	0
six	six	CD	0
months	months	NNS	0
respectively	respectively	RB	0
were	were	VBD	0
not	not	RB	0
eligible	eligible	JJ	0
for	for	IN	0
inclusion	inclusion	NN	0
.	.	.	0
The	The	DT	0
investigator	investigator	NN	B-NP
reasoned	reasoned	VBD	0
that	that	DT	0
recurrent	recurrent	JJ	0
ischemic	ischemic	JJ	B-NP
event	event	NN	I-NP
in	in	IN	0
this	this	DT	0
population	population	NN	0
were	were	VBD	0
likely	likely	JJ	0
to	to	TO	0
result	result	VB	0
from	from	IN	0
restenosi	restenosi	NN	B-NP
or	or	CC	0
bypass	bypass	VB	0
graft	graft	JJ	0
closure	closure	NN	0
and	and	CC	0
that	that	DT	0
statin	statin	NN	B-NP
would	would	MD	0
be	be	VB	0
less	less	RBR	0
likely	likely	JJ	0
to	to	TO	0
affect	affect	VB	0
these	these	DT	0
processes	processes	NNS	0
[	[	-LRB-	0
8	8	CD	0
]	]	-RRB-	0
.	.	.	0
Nevertheless	Nevertheless	RB	0
,	,	,	0
a	a	DT	0
number	number	NN	0
of	of	IN	0
trials	trials	NNS	0
have	have	VBP	0
established	established	VBN	0
the	the	DT	0
benefits	benefits	NNS	0
of	of	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
early	early	RB	0
after	after	IN	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
[	[	-LRB-	0
9	9	CD	0
10	10	CD	0
11	11	CD	0
]	]	-RRB-	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
a	a	DT	0
number	number	NN	0
of	of	IN	0
recent	recent	JJ	0
trials	trials	NNS	0
have	have	VBP	0
suggested	suggested	VBN	0
that	that	IN	0
higher	higher	JJR	0
risk	risk	NN	B-NP
patient	patient	JJ	I-NP
with	with	IN	0
non-ST	non-ST	NN	B-NP
elevation	elevation	NN	I-NP
acute	acute	FW	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
fair	fair	JJ	0
better	better	JJR	0
when	when	WRB	0
an	an	DT	0
early	early	JJ	0
invasive	invasive	JJ	B-NP
strategy	strategy	NN	I-NP
is	is	VBZ	0
applied	applied	VBN	0
[	[	-LRB-	0
12	12	CD	0
13	13	CD	0
14	14	CD	0
]	]	-RRB-	0
and	and	CC	0
it	it	PRP	0
is	is	VBZ	0
not	not	RB	0
uncommon	uncommon	JJ	0
for	for	IN	0
patients	patients	NNS	0
to	to	TO	0
be	be	VB	0
treated	treated	VBN	0
in	in	IN	0
this	this	DT	0
fashion	fashion	NN	0
.	.	.	0
Second	Second	LS	0
,	,	,	0
patients	patients	NNS	0
with	with	IN	0
Q-wave	Q-wave	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
were	were	VBD	0
not	not	RB	0
eligible	eligible	JJ	0
for	for	IN	0
enrollment	enrollment	NN	0
because	because	IN	0
it	it	PRP	0
was	was	VBD	0
felt	felt	VBN	0
that	that	IN	0
statin	statin	NN	B-NP
would	would	MD	0
not	not	RB	0
influence	influence	VB	0
the	the	DT	0
development	development	NN	0
of	of	IN	0
important	important	JJ	0
prognostic	prognostic	NNS	B-NP
determinant	determinant	JJ	I-NP
such	such	JJ	0
as	as	IN	0
left	left	VBN	0
ventricular	ventricular	JJ	B-NP
systolic	systolic	JJ	I-NP
dysfunction	dysfunction	NN	I-NP
,	,	,	0
ventricular	ventricular	JJ	B-NP
arrhythmia	arrhythmia	NN	I-NP
or	or	CC	0
mechanical	mechanical	JJ	B-NP
complication	complication	NN	I-NP
[	[	-LRB-	0
5	5	LS	0
]	]	-RRB-	0
.	.	.	0
Nevertheless	Nevertheless	RB	0
,	,	,	0
patients	patients	NNS	0
who	who	WP	0
develop	develop	VBP	0
electrocardiographic	electrocardiographic	JJ	B-NP
q-wave	q-wave	NN	I-NP
represent	represent	VBP	0
a	a	DT	0
substantial	substantial	JJ	0
proportion	proportion	NN	0
of	of	IN	0
all	all	DT	0
patients	patients	NNS	0
with	with	IN	0
myocardial	myocardial	JJ	B-NP
infarction	infarction	NN	I-NP
.	.	.	0
While	While	IN	0
their	their	PRP$	0
short-term	short-term	JJ	0
risk	risk	NN	0
following	following	VBG	0
hospital	hospital	NN	B-NP
discharge	discharge	NN	I-NP
is	is	VBZ	0
lower	lower	RBR	0
relative	relative	JJ	0
to	to	TO	0
those	those	DT	0
with	with	IN	0
a	a	DT	0
non-Q-wave	non-Q-wave	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
still	still	RB	0
much	much	RB	0
greater	greater	JJR	0
than	than	IN	0
in	in	IN	0
patients	patients	NNS	0
with	with	IN	0
stable	stable	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
need	need	NN	0
for	for	IN	0
secondary	secondary	JJ	B-NP
prevention	prevention	NN	I-NP
in	in	IN	0
this	this	DT	0
population	population	NN	0
is	is	VBZ	0
equally	equally	RB	0
important	important	JJ	0
.	.	.	0
Third	Third	JJ	0
,	,	,	0
despite	despite	IN	0
the	the	DT	0
high	high	JJ	0
risk	risk	NN	B-NP
nature	nature	NN	I-NP
of	of	IN	0
enrolled	enrolled	JJ	0
patients	patients	NNS	0
(	(	-LRB-	0
ie	ie	UH	B-NP
,	,	,	0
electrocardiogram	electrocardiogram	NN	B-NP
[	[	-LRB-	0
electrocardiogram	electrocardiogram	NN	B-NP
]	]	-RRB-	0
changes	changes	NNS	0
and	and	CC	0
/	/	NNP	0
or	or	CC	0
other	other	JJ	0
ischemia	ischemia	CD	B-NP
objective	objective	NN	I-NP
evidence	evidence	NN	I-NP
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
rate	rate	NN	0
of	of	IN	0
platelet	platelet	NN	B-NP
glycoprotein	glycoprotein	NN	I-NP
IIb	IIb	NN	I-NP
/	/	NN	I-NP
IIIa	IIIa	NN	I-NP
inhibitor	inhibitor	NN	I-NP
utilization	utilization	NN	I-NP
was	was	VBD	0
quite	quite	RB	0
low	low	JJ	0
(	(	-LRB-	0
1.1	1.1	CD	0
%	%	NN	0
)	)	-RRB-	0
.	.	.	0
Such	Such	JJ	0
therapy	therapy	NN	0
appears	appears	VBZ	0
to	to	TO	0
be	be	VB	0
cost	cost	VBN	0
effective	effective	JJ	0
[	[	-LRB-	0
15	15	CD	0
16	16	CD	0
]	]	-RRB-	0
,	,	,	0
especially	especially	RB	0
among	among	IN	0
high	high	JJ	0
risk	risk	NN	B-NP
patient	patient	JJ	I-NP
and	and	CC	0
is	is	VBZ	0
recommended	recommended	VBN	0
under	under	IN	0
current	current	JJ	0
American	American	NNP	0
College	College	NNP	0
of	of	IN	0
cardiology/american	cardiology/american	NN	B-NP
heart	heart	NN	I-NP
association	association	NN	I-NP
guideline	guideline	NN	I-NP
[	[	-LRB-	0
17	17	CD	0
]	]	-RRB-	0
.	.	.	0
Fourth	Fourth	JJ	0
,	,	,	0
it	it	PRP	0
may	may	MD	0
not	not	RB	0
be	be	VB	0
possible	possible	JJ	0
to	to	TO	0
ascertain	ascertain	VB	0
whether	whether	IN	0
these	these	DT	0
findings	findings	NNS	0
apply	apply	VBP	0
to	to	TO	0
all	all	DT	0
patients	patients	NNS	0
with	with	IN	0
recent	recent	JJ	0
acute	acute	JJ	0
coronary	coronary	NNS	B-NP
syndrome	syndrome	NN	I-NP
regardless	regardless	RB	0
of	of	IN	0
baseline	baseline	JJ	B-NP
lipid	lipid	NN	I-NP
level	level	JJ	I-NP
.	.	.	0
The	The	DT	0
small	small	JJ	0
difference	difference	NN	0
in	in	IN	0
number	number	NN	0
of	of	IN	0
primary	primary	JJ	B-NP
endpoint	endpoint	JJ	I-NP
event	event	NN	I-NP
between	between	IN	0
atorvastatin	atorvastatin	NN	B-NP
and	and	CC	0
placebo	placebo	JJ	0
groups	groups	NNS	0
make	make	VBP	0
it	it	PRP	0
difficult	difficult	JJ	0
to	to	TO	0
dissect	dissect	VB	0
the	the	DT	0
relationship	relationship	NN	B-NP
between	between	IN	0
baseline	baseline	JJ	B-NP
lipid	lipid	NN	I-NP
level	level	JJ	I-NP
and	and	CC	0
treatment	treatment	NN	B-NP
effect	effect	NN	I-NP
further	further	RBR	0
.	.	.	0
Consequently	Consequently	RB	0
,	,	,	0
it	it	PRP	0
remains	remains	VBZ	0
uncertain	uncertain	JJ	0
whether	whether	IN	0
one	one	PRP	0
can	can	MD	0
extrapolate	extrapolate	VB	0
the	the	DT	0
miracl	miracl	NN	B-NP
trial	trial	NN	I-NP
result	result	NN	I-NP
to	to	TO	0
those	those	DT	0
who	who	WP	0
undergo	undergo	VBP	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	NN	I-NP
shortly	shortly	RB	0
before	before	RB	0
or	or	CC	0
after	after	IN	0
a	a	DT	0
coronary	coronary	JJ	B-NP
event	event	NN	I-NP
,	,	,	0
who	who	WP	0
present	present	VBP	0
with	with	IN	0
a	a	DT	0
Q-wave	Q-wave	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
,	,	,	0
who	who	WP	0
are	are	VBP	0
treated	treated	VBN	0
with	with	IN	0
platelet	platelet	NN	B-NP
glycoprotein	glycoprotein	NN	I-NP
iib/iiia	iib/iiia	NN	I-NP
inhibitor	inhibitor	NN	I-NP
,	,	,	0
or	or	CC	0
who	who	WP	0
have	have	VBP	0
relatively	relatively	RB	0
low	low	JJ	0
admission	admission	NN	B-NP
ldl	ldl	NN	I-NP
cholesterol	cholesterol	NN	I-NP
level	level	JJ	I-NP
.	.	.	0
Time	Time	NN	0
to	to	TO	0
change	change	VB	0
current	current	JJ	0
practice	practice	NN	0
Although	Although	IN	0
MIRACL	MIRACL	NNP	B-NP
and	and	CC	0
the	the	DT	0
two	two	CD	0
aforementioned	aforementioned	JJ	B-NP
cohort	cohort	JJ	I-NP
study	study	NN	I-NP
suggest	suggest	VBP	0
that	that	IN	0
lipid-lowering	lipid-lowering	JJ	B-NP
agent	agent	NN	I-NP
exert	exert	VBP	0
short-term	short-term	JJ	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
when	when	WRB	0
initiated	initiated	VBN	0
soon	soon	RB	0
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
,	,	,	0
this	this	DT	0
remains	remains	VBZ	0
an	an	DT	0
open	open	JJ	0
question	question	NN	0
.	.	.	0
Even	Even	RB	0
if	if	IN	0
these	these	DT	0
findings	findings	NNS	0
are	are	VBP	0
not	not	RB	0
confirmed	confirmed	VBN	0
after	after	IN	0
further	further	JJ	0
study	study	NN	0
,	,	,	0
one	one	PRP	0
could	could	MD	0
still	still	RB	0
make	make	VB	0
a	a	DT	0
compelling	compelling	JJ	0
argument	argument	NN	0
that	that	IN	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
(	(	-LRB-	0
barring	barring	FW	0
contraindication	contraindication	NN	B-NP
)	)	-RRB-	0
should	should	MD	0
be	be	VB	0
initiated	initiated	VBN	0
early	early	JJ	0
and	and	CC	0
universally	universally	RB	0
in	in	IN	0
patients	patients	NNS	0
who	who	WP	0
present	present	VBP	0
with	with	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
:	:	:	0
First	First	NNP	0
,	,	,	0
the	the	DT	0
long-term	long-term	JJ	0
safety	safety	NN	0
and	and	CC	0
effectiveness	effectiveness	NN	0
of	of	IN	0
secondary	secondary	JJ	B-NP
prevention	prevention	NN	I-NP
statin	statin	NN	I-NP
of	of	IN	0
stable	stable	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
is	is	VBZ	0
well-established	well-established	JJ	0
[	[	-LRB-	0
1	1	CD	0
2	2	CD	0
3	3	CD	0
]	]	-RRB-	0
;	;	:	0
Second	Second	LS	0
,	,	,	0
as	as	RB	0
evidenced	evidenced	VBN	0
by	by	IN	0
MIRACL	MIRACL	NNP	B-NP
,	,	,	0
these	these	DT	0
agents	agents	NNS	0
are	are	VBP	0
safe	safe	JJ	0
when	when	WRB	0
initiated	initiated	VBN	0
at	at	IN	0
the	the	DT	0
time	time	NN	0
of	of	IN	0
hospitalization	hospitalization	NN	B-NP
for	for	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
;	;	:	0
Third	Third	LS	0
,	,	,	0
the	the	DT	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
in-hospital	in-hospital	JJ	I-NP
initiation	initiation	NN	I-NP
appears	appears	VBZ	0
to	to	TO	0
promote	promote	VB	0
greater	greater	JJR	0
long-term	long-term	JJ	0
utilization	utilization	NN	0
of	of	IN	0
these	these	DT	0
agents	agents	NNS	0
[	[	-LRB-	0
18	18	CD	0
19	19	CD	0
20	20	CD	0
21	21	CD	0
]	]	-RRB-	0
.	.	.	0
Finally	Finally	RB	0
,	,	,	0
although	although	IN	0
lipid	lipid	JJ	B-NP
level	level	JJ	I-NP
may	may	MD	0
be	be	VB	0
unreliable	unreliable	VBN	0
in	in	IN	0
the	the	DT	0
setting	setting	NN	0
of	of	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
(	(	-LRB-	0
excepting	excepting	JJ	0
total	total	NN	0
:	:	:	0
high	high	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
and	and	CC	0
low	low	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
:	:	:	0
hdl	hdl	NN	B-NP
cholesterol	cholesterol	NN	I-NP
ratio	ratio	NN	I-NP
[	[	-LRB-	0
22	22	CD	0
]	]	CD	0
)	)	-RRB-	0
the	the	DT	0
overwhelming	overwhelming	JJ	0
majority	majority	NN	0
of	of	IN	0
patients	patients	NNS	0
with	with	IN	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
will	will	MD	0
ultimately	ultimately	RB	0
require	require	VB	0
both	both	DT	0
pharmacologic	pharmacologic	NN	B-NP
and	and	CC	0
non-pharmacologic	non-pharmacologic	JJ	B-NP
lipid-lowering	lipid-lowering	JJ	I-NP
intervention	intervention	NN	I-NP
to	to	TO	0
attain	attain	VB	0
recommended	recommended	VBN	B-NP
cholesterol	cholesterol	NN	I-NP
target	target	NN	I-NP
[	[	-LRB-	0
23	23	CD	0
24	24	CD	0
25	25	CD	0
]	]	-RRB-	0
;	;	:	0
newer	newer	JJR	0
guidelines	guidelines	NNS	0
are	are	VBP	0
even	even	RB	0
more	more	RBR	0
stringent	stringent	JJ	0
[	[	-LRB-	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
Furthermore	Furthermore	RB	0
,	,	,	0
data	data	NNS	0
from	from	IN	0
the	the	DT	0
recently	recently	RB	0
presented	presented	VBN	B-NP
Heart	Heart	NNP	I-NP
Protection	Protection	NNP	I-NP
Study	Study	NNP	I-NP
suggest	suggest	VBP	0
that	that	IN	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
may	may	MD	0
accrue	accrue	VB	0
independent	independent	JJ	0
of	of	IN	0
baseline	baseline	JJ	B-NP
cholesterol	cholesterol	NN	I-NP
level	level	NN	I-NP
[	[	-LRB-	0
4	4	LS	0
]	]	-RRB-	0
.	.	.	0
Thus	Thus	RB	0
,	,	,	0
to	to	TO	0
withhold	withhold	VB	0
lipid-lowering	lipid-lowering	JJ	B-NP
therapy	therapy	NN	I-NP
from	from	IN	0
patients	patients	NNS	0
who	who	WP	0
present	present	VBP	0
with	with	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
would	would	MD	0
be	be	VB	0
to	to	TO	0
accept	accept	VB	0
the	the	DT	0
status	status	NN	B-NP
quo	quo	NN	I-NP
,	,	,	0
and	and	CC	0
to	to	TO	0
date	date	VB	0
our	our	PRP$	0
efforts	efforts	NNS	0
at	at	IN	0
cholesterol	cholesterol	NN	B-NP
lowering	lowering	VBG	0
in	in	IN	0
the	the	DT	0
secondary	secondary	JJ	B-NP
prevention	prevention	NN	I-NP
set	set	NN	I-NP
have	have	VBP	0
been	been	VBN	0
dismal	dismal	JJ	0
[	[	-LRB-	0
27	27	CD	0
28	28	CD	0
]	]	-RRB-	0
.	.	.	0
More	More	RBR	0
MIRACLes	MIRACLes	JJ	0
ahead	ahead	RB	0
?	?	.	0
The	The	DT	0
ascertainment	ascertainment	NN	B-NP
and	and	CC	0
quantification	quantification	NN	B-NP
of	of	IN	0
any	any	DT	0
incremental	incremental	JJ	B-NP
benefit	benefit	NN	I-NP
conferred	conferred	NN	I-NP
by	by	IN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
initiated	initiated	VBD	0
early	early	RB	0
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
will	will	MD	0
require	require	VB	0
confirmation	confirmation	NN	B-NP
.	.	.	0
There	There	EX	0
is	is	VBZ	0
currently	currently	RB	0
only	only	RB	0
one	one	CD	0
ongoing	ongoing	JJ	0
randomized	randomized	JJ	B-NP
placebo-controlled	placebo-controlled	JJ	I-NP
trial	trial	NN	I-NP
of	of	IN	0
early	early	JJ	0
versus	versus	NNS	0
delayed	delayed	VBN	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
in	in	IN	0
this	this	DT	0
setting	setting	NN	0
,	,	,	0
A-2-Z	A-2-Z	NNP	B-NP
(	(	-LRB-	0
Aggrastat	Aggrastat	NNP	B-NP
to	to	TO	0
Zocor	Zocor	NNP	B-NP
,	,	,	0
Merck	Merck	NNP	0
)	)	-RRB-	0
[	[	-LRB-	0
29	29	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
A-2-Z	A-2-Z	JJ	B-NP
study	study	NN	I-NP
is	is	VBZ	0
evaluating	evaluating	VBG	0
the	the	DT	0
efficacy	efficacy	NN	0
of	of	IN	0
early	early	JJ	0
treatment	treatment	NN	0
with	with	IN	0
simvastatin	simvastatin	NN	B-NP
in	in	IN	0
4,500	4,500	CD	0
patients	patients	NNS	0
following	following	VBG	0
an	an	DT	0
episode	episode	NN	0
of	of	IN	0
unstable	unstable	JJ	0
angina	angina	NN	0
or	or	CC	0
a	a	DT	0
non-Q	non-Q	JJ	B-NP
wave	wave	NN	I-NP
myocardial	myocardial	NN	I-NP
infarction	infarction	NN	I-NP
.	.	.	0
In	In	IN	0
the	the	DT	0
first	first	JJ	0
four	four	CD	0
months	months	NNS	0
,	,	,	0
patients	patients	NNS	0
will	will	MD	0
be	be	VB	0
randomized	randomized	VBN	0
to	to	TO	0
simvastatin	simvastatin	CD	B-NP
40	40	CD	0
mg	mg	CD	B-NP
daily	daily	JJ	0
or	or	CC	0
placebo	placebo	NN	0
.	.	.	0
Thereafter	Thereafter	RB	0
,	,	,	0
those	those	DT	0
patients	patients	NNS	0
treated	treated	VBN	0
with	with	IN	0
simvastatin	simvastatin	NN	B-NP
in	in	IN	0
the	the	DT	0
first	first	JJ	0
phase	phase	NN	0
will	will	MD	0
receive	receive	VB	0
80	80	CD	0
simvastatin	simvastatin	JJ	B-NP
daily	daily	JJ	I-NP
mg	mg	NN	I-NP
and	and	CC	0
those	those	DT	0
treated	treated	VBN	0
with	with	IN	0
placebo	placebo	NN	0
,	,	,	0
40	40	CD	0
simvastatin	simvastatin	JJ	B-NP
daily	daily	JJ	I-NP
mg	mg	NN	I-NP
.	.	.	0
The	The	DT	0
primary	primary	JJ	B-NP
composite	composite	JJ	I-NP
endpoint	endpoint	NN	I-NP
is	is	VBZ	0
the	the	DT	0
occurrence	occurrence	NN	0
of	of	IN	0
cardiovascular	cardiovascular	JJ	B-NP
death	death	NN	I-NP
,	,	,	0
non-fatal	non-fatal	JJ	B-NP
myocardial	myocardial	JJ	I-NP
infarction	infarction	NN	I-NP
,	,	,	0
or	or	CC	0
rehospitalization	rehospitalization	NN	B-NP
for	for	IN	0
an	an	DT	0
acute	acute	JJ	B-NP
coronary	coronary	JJ	I-NP
syndrome	syndrome	NN	I-NP
(	(	-LRB-	0
ar	ar	NN	B-NP
consensus	consensus	NN	I-NP
sequence	sequence	NN	I-NP
)	)	-RRB-	0
at	at	IN	0
one	one	CD	0
year	year	NN	0
.	.	.	0
If	If	IN	0
A-2-Z	A-2-Z	NNP	B-NP
demonstrates	demonstrates	VBZ	0
significant	significant	JJ	0
reductions	reductions	NNS	0
in	in	IN	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
adverse	adverse	JJ	0
events	events	NNS	0
during	during	IN	0
the	the	DT	0
first	first	JJ	0
four	four	CD	0
months	months	NNS	0
,	,	,	0
it	it	PRP	0
would	would	MD	0
suggest	suggest	VB	0
an	an	DT	0
incremental	incremental	JJ	B-NP
clinical	clinical	JJ	I-NP
benefit	benefit	NN	I-NP
from	from	IN	0
initiating	initiating	VBG	0
these	these	DT	0
agents	agents	NNS	0
early	early	RB	0
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
.	.	.	0
If	If	IN	0
benefits	benefits	NNS	0
accrue	accrue	NN	0
,	,	,	0
but	but	CC	0
do	do	VBP	0
so	so	RB	0
later	later	RB	0
during	during	IN	0
follow	follow	VB	0
up	up	RP	0
,	,	,	0
it	it	PRP	0
would	would	MD	0
be	be	VB	0
difficult	difficult	JJ	0
to	to	TO	0
discriminate	discriminate	VB	0
between	between	IN	0
the	the	DT	0
effects	effects	NNS	0
of	of	IN	0
more	more	RBR	0
aggressive	aggressive	JJ	B-NP
vs.	vs.	NN	0
earlier	earlier	RBR	0
lipid	lipid	JJ	B-NP
lowering	lowering	JJ	I-NP
therapy	therapy	NN	I-NP
.	.	.	0
The	The	DT	0
Pravastatin	Pravastatin	NNP	B-NP
or	or	CC	0
Atorvastatin	Atorvastatin	NNP	B-NP
Evaluation	Evaluation	NNP	I-NP
and	and	CC	0
Infection	Infection	NNP	B-NP
Therapy	Therapy	NNP	I-NP
(	(	-LRB-	0
PROVE	PROVE	NNP	0
IT	IT	NNP	0
)	)	-RRB-	0
trial	trial	NN	0
is	is	VBZ	0
looking	looking	VBG	0
at	at	IN	0
4,000	4,000	CD	0
patients	patients	NNS	0
within	within	IN	0
10	10	CD	0
days	days	NNS	0
of	of	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
and	and	CC	0
randomizing	randomizing	VBD	0
them	them	PRP	0
to	to	TO	0
either	either	DT	0
pravastatin	pravastatin	JJ	0
40	40	CD	0
mg	mg	NN	B-NP
or	or	CC	0
atorvastatin	atorvastatin	CD	B-NP
80	80	CD	0
mg	mg	CD	B-NP
daily	daily	JJ	0
[	[	-LRB-	0
29	29	CD	0
]	]	-RRB-	0
.	.	.	0
Patients	Patients	NNS	0
will	will	MD	0
be	be	VB	0
observed	observed	VBN	0
over	over	RP	0
at	at	IN	0
least	least	JJS	0
1.5	1.5	CD	0
years	years	NNS	0
for	for	IN	0
the	the	DT	0
occurrence	occurrence	NN	0
of	of	IN	0
myocardial	myocardial	JJ	B-NP
infarction	infarction	NN	I-NP
or	or	CC	0
other	other	JJ	0
cardiovascular	cardiovascular	JJ	B-NP
event	event	NN	I-NP
.	.	.	0
Unlike	Unlike	NNP	0
,	,	,	0
MIRACL	MIRACL	NNP	B-NP
and	and	CC	0
the	the	DT	0
a-2-z	a-2-z	NN	B-NP
trial	trial	NN	I-NP
,	,	,	0
this	this	DT	0
study	study	NN	0
will	will	MD	0
not	not	RB	0
assess	assess	VB	0
the	the	DT	0
efficacy	efficacy	NN	0
of	of	IN	0
early	early	JJ	0
statin	statin	JJ	B-NP
therapy	therapy	NN	I-NP
after	after	IN	0
an	an	DT	0
acute	acute	JJ	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
;	;	:	0
rather	rather	RB	0
,	,	,	0
it	it	PRP	0
will	will	MD	0
examine	examine	VB	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
more	more	JJR	0
vs.	vs.	IN	0
less	less	RBR	0
aggressive	aggressive	JJ	0
lipid-lowering	lipid-lowering	NN	0
in	in	IN	0
this	this	DT	0
setting	setting	NN	0
.	.	.	0
In	In	IN	0
2002	2002	CD	0
,	,	,	0
many	many	JJ	0
would	would	MD	0
consider	consider	VB	0
it	it	PRP	0
unethical	unethical	VBP	0
to	to	TO	0
withhold	withhold	VB	0
statins	statins	VBN	0
from	from	IN	0
patients	patients	NNS	0
with	with	IN	0
established	established	JJ	0
coronary	coronary	JJ	B-NP
disease	disease	NN	I-NP
.	.	.	0
This	This	DT	0
makes	makes	VBZ	0
it	it	PRP	0
unlikely	unlikely	RB	0
that	that	IN	0
additional	additional	JJ	0
placebo-controlled	placebo-controlled	JJ	0
trials	trials	NNS	0
will	will	MD	0
be	be	VB	0
carried	carried	VBN	0
out	out	RP	0
in	in	IN	0
this	this	DT	0
area	area	NN	0
.	.	.	0
future	future	JJ	B-NP
secondary	secondary	JJ	I-NP
prevention	prevention	NN	I-NP
study	study	NN	I-NP
should	should	MD	0
look	look	VB	0
at	at	IN	0
patients	patients	NNS	0
with	with	IN	0
stable	stable	JJ	0
or	or	CC	0
unstable	unstable	JJ	0
disease	disease	NN	0
and	and	CC	0
will	will	MD	0
need	need	VB	0
to	to	TO	0
address	address	VB	0
the	the	DT	0
comparative	comparative	JJ	B-NP
efficacy	efficacy	NN	I-NP
of	of	IN	0
different	different	JJ	0
statin	statin	NN	B-NP
(	(	-LRB-	0
or	or	CC	0
newer	newer	JJR	0
agents	agents	NNS	0
)	)	-RRB-	0
,	,	,	0
assess	assess	VB	0
the	the	DT	0
combination	combination	NN	B-NP
therapy	therapy	NN	I-NP
incremental	incremental	JJ	I-NP
benefit	benefit	NN	I-NP
[	[	-LRB-	0
30	30	CD	0
]	]	-RRB-	0
and	and	CC	0
determine	determine	VB	0
whether	whether	IN	0
there	there	EX	0
is	is	VBZ	0
a	a	DT	0
serum	serum	JJ	B-NP
cholesterol	cholesterol	NN	I-NP
'	'	POS	0
floor	floor	NN	0
'	'	''	0
below	below	IN	0
which	which	WDT	0
reductions	reductions	NNS	0
are	are	VBP	0
unlikely	unlikely	JJ	0
to	to	TO	0
provide	provide	VB	0
further	further	RBR	0
clinical	clinical	JJ	B-NP
benefit	benefit	NN	I-NP
.	.	.	0
competing	competing	VBG	B-NP
interest	interest	NN	I-NP
Dr	Dr	NNP	0
Aronow	Aronow	NNP	0
has	has	VBZ	0
received	received	VBN	0
honoraria	honoraria	VBN	0
as	as	IN	0
a	a	DT	0
speaker	speaker	NN	0
and	and	CC	0
pfizer	pfizer	NN	B-NP
advisory	advisory	JJ	I-NP
board	board	NN	I-NP
member	member	NN	I-NP
and	and	CC	0
as	as	IN	0
a	a	DT	0
speaker	speaker	NN	0
for	for	IN	0
Merck	Merck	NNP	0
.	.	.	0
hmg	hmg	NN	B-NP
coa	coa	NN	I-NP
abbreviation	abbreviation	NN	I-NP
=	=	SYM	0
3-Hydroxy-3-methylgluatryl	3-Hydroxy-3-methylgluatryl	FW	0
coenzyme	coenzyme	FW	0
A	A	NNP	0
;	;	:	0
MIRACL	MIRACL	NNP	B-NP
=	=	NNP	0
Myocardial	Myocardial	NNP	B-NP
Ischemia	Ischemia	NNP	I-NP
Reduction	Reduction	NNP	I-NP
with	with	IN	0
Aggressive	Aggressive	NNP	B-NP
Cholesterol	Cholesterol	NNP	I-NP
Lowering	Lowering	NNP	0
;	;	:	0
low	low	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
=	=	SYM	0
low	low	JJ	0
density	density	NN	B-NP
lipoprotein	lipoprotein	NN	I-NP
;	;	:	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
=	=	SYM	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
;	;	:	0
CI	CI	NNP	0
=	=	SYM	0
confidence	confidence	NN	B-NP
interval	interval	NN	I-NP
;	;	:	0
high	high	JJ	B-NP
density	density	NN	I-NP
lipoprotein	lipoprotein	NN	I-NP
=	=	SYM	0
high	high	JJ	0
density	density	NN	B-NP
lipoprotein	lipoprotein	NN	I-NP
;	;	:	0
percutaneou	percutaneou	NN	B-NP
transluminal	transluminal	NN	I-NP
coronary	coronary	JJ	I-NP
angioplasty	angioplasty	NN	I-NP
=	=	SYM	0
percutaneou	percutaneou	NN	B-NP
transluminal	transluminal	NN	I-NP
coronary	coronary	JJ	I-NP
angioplasty	angioplasty	NN	I-NP
;	;	:	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
bypass	bypass	NN	I-NP
graft	graft	NN	I-NP
=	=	SYM	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
bypass	bypass	NN	I-NP
graft	graft	NN	I-NP
;	;	:	0
electrocardiogram	electrocardiogram	NN	B-NP
=	=	SYM	0
electrocardiogram	electrocardiogram	FW	0
;	;	:	0
A-2-Z	A-2-Z	CD	B-NP
=	=	SYM	0
Aggrastat	Aggrastat	NNP	B-NP
to	to	TO	0
Zocor	Zocor	NNP	B-NP
;	;	:	0
acute	acute	JJ	B-NP
coronary	coronary	JJ	I-NP
syndrome	syndrome	NN	I-NP
=	=	SYM	0
acute	acute	FW	0
coronary	coronary	JJ	B-NP
syndrome	syndrome	NN	I-NP
;	;	:	0
PROVE	PROVE	NNP	0
IT	IT	NNP	0
=	=	NNP	0
Pravastatin	Pravastatin	NNP	B-NP
or	or	CC	0
Atorvastatin	Atorvastatin	NNP	B-NP
Evaluation	Evaluation	NNP	I-NP
and	and	CC	0
Infection	Infection	NNP	B-NP
Therapy	Therapy	NNP	I-NP
.	.	.	0
